Andrew Wagner

Andrew Wagner

Auto-generated profile, based on publicly available information

Andrew Wagner

Division of Pulmonary Biology Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2023 in Science Advances
Verified
Journal Article
Open access
TOTasnim Olatoke
Tasnim Olatoke
AWAndrew Wagner
Andrew Wagner
AAAristotelis Astrinidis
Aristotelis Astrinidis
EZErik Y. Zhang
Erik Y. Zhang
MGMinzhe Guo
Minzhe Guo
JYJane J. Yu
Jane J. Yu
Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that predominantly affects women. LAM cells carry TSC1/TSC2 mutations, causing mTORC1 hyperactivation and uncontrolled cell growth. mTORC1 inhibitors stabilize lung function; however, sustained efficacy requires long-term administration, and some patients fail to tolerate or respond to therapy. Although the genetic basis of LAM is known, mechanisms underlying LAM pathogenesis remain elusive. We integrated single-cell RNA sequencing and single-nuclei ATAC-seq of LAM lungs to construct a gene regulatory network controlling the transcriptional program of LAM cells. We identified activation of uterine-specific HOX-PBX transcriptional programs in pulmonary LAM CORE cells as regulators of cell survival depending upon HOXD11-PBX1 dimerization. Accordingly, blockage of HOXD11-PBX1 dimerization by HXR9 suppressed LAM cell survival in vitro and in vivo. PBX1 regulated STAT1/3, increased the expression of antiapoptotic genes, and promoted LAM cell survival in vitro. The HOX-PBX gene network provides promising targets for treatment of LAM/TSC mTORC1-hyperactive cancers.

7 January 2026 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
SASara Alharbi
Sara Alharbi
AWAndrew Wagner
Andrew Wagner
SMSvatava Merkle
Svatava Merkle
PPPatricia Pastura
Patricia Pastura
CMC. Griffin McDaniel
C. Griffin McDaniel
TCTimothy D. Le Cras
Timothy D. Le Cras

10 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KCKen Chen
Ken Chen
SZShuyang Zhao
Shuyang Zhao
MGMinzhe Guo
Minzhe Guo
HRHasan Reza
Hasan Reza
AWAndrew Wagner
Andrew Wagner
YXYan Xu
Yan Xu
Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease characterized by cystic destruction and metastatic growth of smooth muscle-like cells. Despite advances in understanding its genetic basis, the cellular heterogeneity, regulatory mechanisms, and microenvironmental interactions driving LAM progression remain poorly defined. In this study, we employed an integrative multi-omics approach combining single-cell RNA sequencing (scRNA-seq), single-nucleus ATAC sequencing (snATAC-seq), and high-resolution spatial transcriptomics (Visium, Visium HD, and Xenium) to decode the LAM niche in its native environment. We identified two spatially and functionally distinct LAM subtypes: LAM CORE1 and LAM CORE2 . LAM CORE1 cells exhibited a uterine smooth muscle-like phenotype, expressing associated markers ( ACTA2 , MYH11 ) and were enriched in MTORC1 signaling and myogenic pathways, supporting a uterine origin. In contrast, LAM CORE2 cells displayed fibroblast-like features, with upregulated extracellular matrix (ECM) remodeling genes ( COL1A1 , MMP11 ) and epithelial-to-mesenchymal transition (EMT) pathways, suggesting a role in niche formation. Pseudotime and regulon analyses revealed dynamic transitions between these subtypes, driven by distinct transcriptional networks (e.g., HOX/PBX in LAM CORE1 , TWIST/ZEB in LAM CORE2 ). The presence of the two distinct LAM subtypes was further validated by RNAscope and immunofluorescence microscopy. We identified LAM-associated fibroblasts (LAFs) as activated stromal cells expressing canonical markers ( FAP , S100A4 , VIM, IGFBP7, SPARC ) and localized within LAM lesions. Subpopulations of LAFs, LAF-seed (proximal to LAM CORE1 ) and LAF-niche (surrounding LAM niches), exhibited unique functional profiles, including ECM deposition, TGF-β signaling, and myofibroblast activation. Regulatory network analysis pinpointed EGR1 as a central hub governing LAF phenotype. Our comprehensive spatial profiling revealed niche structures dominated by LAM CORE1 cells and surrounded by lymphatic endothelial cells (LECs), LAFs, scattered LAM CORE2 cells, macrophages, and reprogrammed alveolar epithelial cells (AT2). ECM remodeling and aberrant organization of cable-like structures (α-smooth muscle actin+) of the LAM niches were further validated by second harmonic generation microscopy. These findings provide a high-resolution blueprint of LAM pathogenesis, highlighting the interplay between uterine-derived LAM CORE cells, activated fibroblasts, and the remodeled lung microenvironment. They significantly enhance our understanding of the LAM niche microenvironment and offer insights into potential therapeutic targets and strategies for managing this complex disease.

5 November 2021
Verified
Book Chapter
Closed access
RBRobert G. Best
Robert G. Best
Vineet BhandariVineet Bhandari
Vineet Bhandari
JDJeffrey S. Dungan
Jeffrey S. Dungan
RERichard W. Erbe
Richard W. Erbe
JGJames D. Goldberg
James D. Goldberg
SYSvetlana Yatsenko
Svetlana Yatsenko